What the July PCAC Meeting Means for Your Peptides

What's Happening July 23–24

Mark the date: on July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee (PCAC) meets to formally weigh in on a question a lot of our readers have been asking since spring — what happens next for the peptides that got pulled off the FDA's restricted Category 2 list back in April?

That April move freed up twelve peptides that had been sitting in regulatory limbo: BPC-157, CJC-1295, GHK-Cu, Ipamorelin, TB-500, AOD-9604, Selank, Semax, and a handful of others. Coming off Category 2 was a real step forward, but it never meant these peptides were cleared for compounding pharmacies to make and dispense the way approved drugs are. That's a separate, more formal process — and the PCAC meeting is where it gets decided.

The Backstory, Quickly

The FDA's compounding rules sort substances into buckets. Category 2 is essentially a "do not compound" list — usually because of safety concerns or insufficient data. Getting removed from Category 2 just means a substance is no longer actively blocked; it doesn't automatically move a peptide onto the 503A "bulk drug substances" list that lets compounding pharmacies legally prepare it for patients. That's the step PCAC is being asked to consider this month, for a subset of the returned peptides currently under committee review — reporting has named BPC-157, KPV, TB-500, and MOTS-C specifically among those on the agenda.

Today's Development: FDA's Own Scientists Push Back

Here's what's new as of this week. NPR reported on July 8 that FDA's own scientific staff — the agency's internal reviewers, not outside critics — have recommended against changing the compounding status of any of the peptides currently under review. That's notable: it's not an outside advocacy group or a competing industry raising concerns, it's the FDA's own scientific team.

NPR's reporting also flagged something else worth sitting with: several PCAC panel members reportedly have industry ties to peptide clinics or compounding pharmacies — the exact businesses that stand to benefit financially if the committee recommends a favorable ruling.

Why the Conflict-of-Interest Question Matters

To be clear, having industry experience isn't automatically disqualifying — advisory committees are often built from people who know a field well, and that usually means people who've worked in it. But when the agency's own scientific staff is recommending caution and some of the people voting on the outcome have a direct financial stake in the opposite result, it's a legitimate thing for anyone following this space to watch closely. We'll be covering how the committee actually votes once the meeting wraps.

What This Means for Research Peptide Buyers Right Now

Nothing changes today. The peptides named above remain in the same regulatory position they've been in since April — off Category 2, not yet cleared for compounding. If you're a research-use buyer working with vendors selling these compounds for laboratory or research purposes (not as a compounded prescription product), this vote doesn't directly touch that market. But it's a signal worth watching, because outcomes here often shape the broader conversation around which peptides get more scrutiny, more testing requirements, or more mainstream medical acceptance down the line.

We'll publish a follow-up after the July 23–24 meeting with the actual vote and what it means going forward.